FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2140688081> ?p ?o ?g. }

• W2140688081 endingPage "1232" @default.
• W2140688081 startingPage "1223" @default.
• W2140688081 abstract "The CRTH2 antagonist OC000459 has previously been demonstrated to reduce airway inflammation and improve lung function in moderate persistent asthma. A study was conducted to determine the effect of lower once daily doses of OC000459 and to define the phenotype of subjects most responsive to treatment.Adult subjects (percentage of predicted forced expiratory volume in 1 s (FEV1 ) 60-85%) were randomized to OC000459 at three dose levels (25 mg once daily, 200 mg once daily or 100 mg twice daily) or placebo for 12 weeks (n = 117-125 per group, full analysis set). The primary endpoint was the change from baseline in prebronchodilator FEV1 , and secondary endpoints included Asthma Control Questionnaire (ACQ) and Standardised Asthma Quality of Life Questionnaire [AQLQ(S)], and incidence of exacerbations and respiratory tract infections.OC459 caused a significant improvement in FEV1 compared with placebo at a dose of 25 mg once daily (P = 0.028). A similar increase was observed in the other dose groups, and the mean change in FEV1 in the pooled dose groups at endpoint was 95 ml greater than placebo (P = 0.024). In a post hoc analysis of atopic eosinophilic subjects with uncontrolled asthma, a mean increase in FEV1 of 220 ml was observed compared with placebo (P = 0.005). The mean increase in FEV1 was more marked in younger subjects in this group: for subjects aged ≤40 years, there was a mean increase of 355 ml compared with placebo (P = 0.007). Improvements in ACQ and AQLQ(S) were observed in both the full analysis set and the atopic eosinophilic subgroup. There was a lower incidence of exacerbations and respiratory infections in subjects treated with OC000459. There were no drug-related serious adverse events.OC000459 is a safe and effective oral anti-inflammatory agent, which achieved clinically meaningful improvements in lung function and asthma control in allergic asthmatics with an eosinophil-dominant form of the disease. A dose of 25 mg given once daily was as effective as the higher doses studied." @default.
• W2140688081 created "2016-06-24" @default.
• W2140688081 creator A5004774340 @default.
• W2140688081 creator A5010845195 @default.
• W2140688081 creator A5022703304 @default.
• W2140688081 creator A5022911509 @default.
• W2140688081 creator A5028196368 @default.
• W2140688081 creator A5063476882 @default.
• W2140688081 creator A5064464676 @default.
• W2140688081 creator A5078390502 @default.
• W2140688081 creator A5081647219 @default.
• W2140688081 date "2014-07-14" @default.
• W2140688081 modified "2023-10-06" @default.
• W2140688081 title "Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459" @default.
• W2140688081 cites W1512168554 @default.
• W2140688081 cites W1916962812 @default.
• W2140688081 cites W1988758075 @default.
• W2140688081 cites W2006698613 @default.
• W2140688081 cites W2033050749 @default.
• W2140688081 cites W2055418771 @default.
• W2140688081 cites W2062918919 @default.
• W2140688081 cites W2064998500 @default.
• W2140688081 cites W2095754126 @default.
• W2140688081 cites W2100872205 @default.
• W2140688081 cites W2106715003 @default.
• W2140688081 cites W2108919922 @default.
• W2140688081 cites W2121804671 @default.
• W2140688081 cites W2124251887 @default.
• W2140688081 cites W2127482775 @default.
• W2140688081 cites W2138954494 @default.
• W2140688081 cites W2150035260 @default.
• W2140688081 cites W2153395214 @default.
• W2140688081 cites W2163430049 @default.
• W2140688081 cites W2164756500 @default.
• W2140688081 cites W2166893697 @default.
• W2140688081 cites W2167829087 @default.
• W2140688081 cites W2312870247 @default.
• W2140688081 cites W2313856416 @default.
• W2140688081 doi "https://doi.org/10.1111/all.12451" @default.
• W2140688081 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24866478" @default.
• W2140688081 hasPublicationYear "2014" @default.
• W2140688081 type Work @default.
• W2140688081 sameAs 2140688081 @default.
• W2140688081 citedByCount "124" @default.
• W2140688081 countsByYear W21406880812014 @default.
• W2140688081 countsByYear W21406880812015 @default.
• W2140688081 countsByYear W21406880812016 @default.
• W2140688081 countsByYear W21406880812017 @default.
• W2140688081 countsByYear W21406880812018 @default.
• W2140688081 countsByYear W21406880812019 @default.
• W2140688081 countsByYear W21406880812020 @default.
• W2140688081 countsByYear W21406880812021 @default.
• W2140688081 countsByYear W21406880812022 @default.
• W2140688081 countsByYear W21406880812023 @default.
• W2140688081 crossrefType "journal-article" @default.
• W2140688081 hasAuthorship W2140688081A5004774340 @default.
• W2140688081 hasAuthorship W2140688081A5010845195 @default.
• W2140688081 hasAuthorship W2140688081A5022703304 @default.
• W2140688081 hasAuthorship W2140688081A5022911509 @default.
• W2140688081 hasAuthorship W2140688081A5028196368 @default.
• W2140688081 hasAuthorship W2140688081A5063476882 @default.
• W2140688081 hasAuthorship W2140688081A5064464676 @default.
• W2140688081 hasAuthorship W2140688081A5078390502 @default.
• W2140688081 hasAuthorship W2140688081A5081647219 @default.
• W2140688081 hasConcept C126322002 @default.
• W2140688081 hasConcept C142724271 @default.
• W2140688081 hasConcept C159110408 @default.
• W2140688081 hasConcept C168563851 @default.
• W2140688081 hasConcept C203092338 @default.
• W2140688081 hasConcept C204787440 @default.
• W2140688081 hasConcept C27081682 @default.
• W2140688081 hasConcept C2776042228 @default.
• W2140688081 hasConcept C2776178081 @default.
• W2140688081 hasConcept C2776238763 @default.
• W2140688081 hasConcept C2777714996 @default.
• W2140688081 hasConcept C2779951463 @default.
• W2140688081 hasConcept C42219234 @default.
• W2140688081 hasConcept C67761136 @default.
• W2140688081 hasConcept C71924100 @default.
• W2140688081 hasConcept C90924648 @default.
• W2140688081 hasConceptScore W2140688081C126322002 @default.
• W2140688081 hasConceptScore W2140688081C142724271 @default.
• W2140688081 hasConceptScore W2140688081C159110408 @default.
• W2140688081 hasConceptScore W2140688081C168563851 @default.
• W2140688081 hasConceptScore W2140688081C203092338 @default.
• W2140688081 hasConceptScore W2140688081C204787440 @default.
• W2140688081 hasConceptScore W2140688081C27081682 @default.
• W2140688081 hasConceptScore W2140688081C2776042228 @default.
• W2140688081 hasConceptScore W2140688081C2776178081 @default.
• W2140688081 hasConceptScore W2140688081C2776238763 @default.
• W2140688081 hasConceptScore W2140688081C2777714996 @default.
• W2140688081 hasConceptScore W2140688081C2779951463 @default.
• W2140688081 hasConceptScore W2140688081C42219234 @default.
• W2140688081 hasConceptScore W2140688081C67761136 @default.
• W2140688081 hasConceptScore W2140688081C71924100 @default.
• W2140688081 hasConceptScore W2140688081C90924648 @default.
• W2140688081 hasIssue "9" @default.
• W2140688081 hasLocation W21406880811 @default.

• next